国际站：Monalizumab

AS：1228763-95-8

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Monalizumab (IPH2201) 是一种靶向自然杀伤细胞群 2A (NKG2A) 的免疫检查点抑制剂。Monalizumab 是一种人源化抗 NKG2A 的单克隆抗体，可增加 IFN-γ 产生，从而促进自然杀伤细胞功能。Monalizumab 可用于头颈部鳞状细胞癌 (HNSCC) 的研究。

体外：Monalizumab 阻断 NKG2A 并增强 CLL NK 细胞介导的针对表达 HLA-E 的 K562 细胞的细胞毒性[3]。Monalizumab 增强 Enzalutamide (HY-70002) (10 μM) 诱导的 NK 细胞活化和杀伤前列腺癌细胞 (LNCaP 和 22Rv1)[5]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内：Monalizumab (50 μg，瘤内注射，与 800 万个活化的 NK 细胞一起) 可有效抑制免疫缺陷小鼠异种移植 HLA-E+ 肿瘤的肿瘤生长[4]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell[4] Dosage: 50 μg, together with 8 millions of activated NK cells Administration: intratumoral injections Result: Shows a synergestic antitumor effect. Enhanced NK-cell killing, and induces lysis of tumor cells. Clinical Trial

参考文献：

[1]. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263.

[2]. Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020 Sep 21;12(9):2691.

[3]. McWilliams EM, et al. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016 Sep 9;5(10):e1226720.

[4]. Melero I, et al. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. EMBO Mol Med. 2023 Nov 8;15(11):e17804.

[5]. Maximilian Pinho-Schwermann, et al. Androgen receptor signaling blockade enhances NK cell-mediated killing of prostate cancer cells and sensitivity to NK cell checkpoint blockade.doi https://doi.org/10.1101/2023.11.15.567201